Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27483474 | 0.97 | ENPP2 (0.54) | ENPP2PTGS2 | |
| SCHEMBL2376239 | 0.85 | ENPP2 (0.72) | ENPP2PTGS2 | |
| SCHEMBL10300269 | 0.77 | PTGS2 (0.62) | ENPP2PTGS2 | |
| SCHEMBL21627142 | 0.77 | ALDH1A1 (0.52) | — | |
| SCHEMBL17548700 | 0.77 | ENPP2 (0.62) | ENPP2PTGS2 | |
| SCHEMBL7677302 | 0.77 | PTGS2 (0.62) | ENPP2PTGS2 | |
| Bromide SCHEMBL28502358 | 0.76 | ENPP2 (0.54) | ENPP2PTGS2 | |
| SCHEMBL12807 | 0.74 | GAA (0.65) | ENPP2PTGS2 | |
| SCHEMBL28182477 | 0.74 | GAA (0.65) | ENPP2PTGS2 | |
| SCHEMBL517832 | 0.74 | ENPP2 (0.59) | ENPP2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113330001-A | 3, 3-difluoroallylamine or salt thereof and pharmaceutical composition containing same | 柳韩洋行 | 2021-08-31 | — | — | CN | disclosed |
| WO-2020240492-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-12-03 | — | — | WO | disclosed |
| EP-3214079-B1 | SIX-MEMBERED RING BENZO DERIVATIVES AS DPP-4 INHIBITOR AND USE THEREOF | UNIV EAST CHINA SCIENCE & TECH (CN) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019190117-A1 | 2-CYANOPYRIMIDIN-4-YL CARBAMATE OR UREA DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | 한림제약(주) | 2019-10-03 | — | — | WO | disclosed |
| CN-109415381-A | Thiazolopyridine derivatives as GPR119 agonist | 人类制药有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-109415359-A | heterocyclic GPR119 agonist compounds | 人类制药有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-107922407-A | Respiratory Syncytial Virus(RSV) inhibitor | 美迪维尔公司 | 2018-04-17 | — | — | CN | disclosed |
| EP-3246034-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | Anacor Pharmaceuticals, Inc. (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-3214079-A1 | SIX-MEMBERED RING BENZO DERIVATIVES AS DPP-4 INHIBITOR AND USE THEREOF | East China University Of Science And Technology (CN) | 2017-09-06 | — | — | EP | disclosed |
| WO-2017117529-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20100090590-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND METHOD OF PRODUCING ORGANIC DEVICE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100045174-A1 | COMPOSITION FOR USE IN ORGANIC DEVICE, POLYMER FILM, AND ORGANIC ELECTROLUMINESCENT ELEMENT | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| US-7638527-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090309070-A1 | COMPOSITIONS FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ORGANIC ELECTROLUMINESCENT DEVICE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090033208-A1 | FILM FORMING COMPOSITION AND ORGANIC ELECTROLUMINESCENT DEVICE | PIONEER CORPORATION (JP) | 2009-02-05 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| EP-1944305-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | ADOLOR CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| EP-1511751-B1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | NEOGENESIS PHARMACEUTICALS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008010061-A2 | 3-AZABICYCLO [3.1.0] HEXANE VANILLOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | OPRK1, OPRD1, OPRL1 | ENPP2 2264/4885PTGS2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.